File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon

TitleBone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon
Authors
Issue Date2001
PublisherAmerican Society for Clinical Pathology. The Journal's web site is located at http://www.ajcp.com
Citation
American Journal Of Clinical Pathology, 2001, v. 115 n. 2, p. 266-270 How to Cite?
AbstractTo look for subtle evidence of marrow involvement in nasal NK cell lymphoma at diagnosis, we retrospectively studied trephine biopsy specimens from 25 consecutive patients by 2 sensitive techniques: CD56 immunohistochemistry and Epstein-Barr virus-encoded RNA in situ hybridization (EBER ISH). Only 2 patients had marrow involvement by NK cell lymphoma at diagnosis. In 3 additional patients, marrow involvement developed during or after systemic recurrence. All 5 positive cases were revealed by EBER ISH, but only 3 cases showed CD56 immunoreactivity. Among the 5 cases, only 2 were recognized by morphologic assessment. All 5 patients died, often within a short period, compared with a mortality of 50% for patients without demonstrable marrow involvement. Marrow involvement is distinctly uncommon in nasal NK cell lymphoma at diagnosis, and EBER ISH is the most sensitive technique for the demonstration of occult NK cell lymphoma. Despite the low frequency of marrow involvement in nasal NK cell lymphoma, EBER ISH is worthwhile to identify the minor subgroup of patients with a high likelihood of early death due to disease and when autologous bone marrow or peripheral blood stem cell transplantation is contemplated.
Persistent Identifierhttp://hdl.handle.net/10722/148237
ISSN
2015 Impact Factor: 2.278
2015 SCImago Journal Rankings: 1.129
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, KFen_US
dc.contributor.authorChan, JKCen_US
dc.contributor.authorCheung, MMCen_US
dc.contributor.authorSo, JCCen_US
dc.date.accessioned2012-05-29T06:11:42Z-
dc.date.available2012-05-29T06:11:42Z-
dc.date.issued2001en_US
dc.identifier.citationAmerican Journal Of Clinical Pathology, 2001, v. 115 n. 2, p. 266-270en_US
dc.identifier.issn0002-9173en_US
dc.identifier.urihttp://hdl.handle.net/10722/148237-
dc.description.abstractTo look for subtle evidence of marrow involvement in nasal NK cell lymphoma at diagnosis, we retrospectively studied trephine biopsy specimens from 25 consecutive patients by 2 sensitive techniques: CD56 immunohistochemistry and Epstein-Barr virus-encoded RNA in situ hybridization (EBER ISH). Only 2 patients had marrow involvement by NK cell lymphoma at diagnosis. In 3 additional patients, marrow involvement developed during or after systemic recurrence. All 5 positive cases were revealed by EBER ISH, but only 3 cases showed CD56 immunoreactivity. Among the 5 cases, only 2 were recognized by morphologic assessment. All 5 patients died, often within a short period, compared with a mortality of 50% for patients without demonstrable marrow involvement. Marrow involvement is distinctly uncommon in nasal NK cell lymphoma at diagnosis, and EBER ISH is the most sensitive technique for the demonstration of occult NK cell lymphoma. Despite the low frequency of marrow involvement in nasal NK cell lymphoma, EBER ISH is worthwhile to identify the minor subgroup of patients with a high likelihood of early death due to disease and when autologous bone marrow or peripheral blood stem cell transplantation is contemplated.en_US
dc.languageengen_US
dc.publisherAmerican Society for Clinical Pathology. The Journal's web site is located at http://www.ajcp.comen_US
dc.relation.ispartofAmerican Journal of Clinical Pathologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAmsacrine - Administration & Dosageen_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshBleomycin - Administration & Dosageen_US
dc.subject.meshBone Marrow - Chemistry - Pathologyen_US
dc.subject.meshChemotherapy, Adjuvanten_US
dc.subject.meshCyclophosphamide - Administration & Dosageen_US
dc.subject.meshCytarabine - Administration & Dosageen_US
dc.subject.meshEpirubicin - Administration & Dosageen_US
dc.subject.meshEtoposide - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunoenzyme Techniquesen_US
dc.subject.meshIn Situ Hybridizationen_US
dc.subject.meshKiller Cells, Natural - Chemistry - Pathologyen_US
dc.subject.meshLymphoma - Chemistry - Pathology - Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMethotrexate - Administration & Dosageen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNose Neoplasms - Chemistry - Pathology - Therapyen_US
dc.subject.meshPrednisone - Administration & Dosageen_US
dc.subject.meshRna, Viral - Analysisen_US
dc.subject.meshRadiotherapyen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshVincristine - Administration & Dosageen_US
dc.titleBone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommonen_US
dc.typeArticleen_US
dc.identifier.emailSo, JCC:scc@pathology.hku.hken_US
dc.identifier.authoritySo, JCC=rp00391en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1309/E5PR-6A9R-Q02N-8QVWen_US
dc.identifier.pmid11211616-
dc.identifier.scopuseid_2-s2.0-0035126174en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035126174&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume115en_US
dc.identifier.issue2en_US
dc.identifier.spage266en_US
dc.identifier.epage270en_US
dc.identifier.isiWOS:000166658500014-
dc.publisher.placeUnited Statesen_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats